Quarterly ResultAug 6, 2026, 04:09 PM
ALX Oncology Q2 Net Loss $(17.97)M; Cash & Investments $153.4M
AI Summary
ALX Oncology Holdings Inc. reported a net loss of $(17.97) million for the second quarter of 2026, an improvement from $(25.95) million in the prior year. The company significantly strengthened its financial position, with cash and investments totaling $153.4 million as of June 30, 2026, up from $48.3 million at year-end 2025, primarily due to proceeds from equity offerings. Operating expenses decreased, and the company terminated its Palo Alto lease, resulting in a gain.
Key Highlights
- Q2 2026 net loss improved to $(17.97) million from $(25.95) million year-over-year.
- Net loss per share for Q2 2026 was $(0.13), compared to $(0.49) in Q2 2025.
- Cash and cash equivalents increased to $22.69 million as of June 30, 2026.
- Short-term investments surged to $115.54 million from $28.42 million at year-end 2025.
- Total assets grew to $160.82 million from $59.05 million as of December 31, 2025.
- Proceeds from equity offerings totaled $150.00 million for the six months ended June 30, 2026.
- Research and development expenses decreased to $13.14 million in Q2 2026 from $18.02 million.
- The company terminated its Palo Alto lease in May 2026, resulting in a gain of $0.24 million.
Price Impact
More from ALXO